The Selank vs Semax comparison is one of the most common questions in nootropic peptide research, and for good reason. Both peptides were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, both are administered intranasally, and both have demonstrated cognitive-enhancing and neuroprotective properties in published research. Yet despite their shared origins, Selank and Semax operate through fundamentally different mechanisms, target different neurotransmitter systems, and serve distinct research applications.
This guide breaks down the science behind each peptide, compares their mechanisms head-to-head, and explores what the research says about using them individually or in combination.
Research Use Only Disclaimer: Selank and Semax are research peptides not approved by the FDA for any medical use. All findings discussed below are from preclinical research and limited clinical studies conducted primarily in Russia. These peptides are sold for laboratory research purposes only. VMAX Peptides does not make therapeutic claims.
Key Takeaways:
| Feature | Selank | Semax |
| Origin | Tuftsin analog (immunomodulatory peptide) | ACTH(4-10) analog (adrenocorticotropic hormone fragment) |
| Structure | Heptapeptide (7 amino acids) | Heptapeptide (7 amino acids) |
| Primary Research Focus | Anxiolytic (anti-anxiety) | Cognitive enhancement / neuroprotection |
| Key Neurotransmitter Systems | GABA, serotonin, enkephalins | BDNF, dopamine, serotonin |
| Administration Route | Intranasal spray | Intranasal spray |
| Crosses Blood-Brain Barrier | N-Acetyl Selank Amidate (NASA) | N-Acetyl Semax Amidate (NASA) |
| Developed By | Institute of Molecular Genetics, Russian Academy of Sciences | Institute of Molecular Genetics, Russian Academy of Sciences |
| Regulatory Status (Russia) | Approved anxiolytic medication | Approved for stroke recovery and cognitive disorders |
| Regulatory Status (USA) | Research peptide — not FDA approved | Research peptide — not FDA approved |
Selank (TP-7) is a synthetic heptapeptide created by combining the naturally occurring immunopeptide tuftsin (Thr-Lys-Pro-Arg) with a stabilizing sequence (Pro-Gly-Pro) to enhance its resistance to enzymatic degradation. This structural modification allows Selank to survive long enough to cross the blood-brain barrier and exert its effects on the central nervous system.
In Russian clinical practice, Selank has been approved as an anxiolytic medication since the mid-2000s. However, in the United States it remains classified as a research peptide without FDA approval.
The primary mechanism of Selank centers on its modulation of the GABAergic system — the brain’s primary inhibitory neurotransmitter network. By enhancing GABA activity, Selank produces anxiolytic effects without the sedation, cognitive impairment, or addiction risk associated with benzodiazepine drugs that target the same system.
Beyond GABA modulation, Selank research has documented effects on several additional pathways. It influences serotonin metabolism, potentially contributing to mood stabilization. It modulates enkephalin levels — endogenous opioid peptides involved in stress response and emotional regulation. And, staying true to its tuftsin origins, Selank retains immunomodulatory properties, influencing cytokine expression and immune cell activity.
Selank benefits documented in research include:
Reduction of anxiety-like behaviors in animal models without sedation or motor impairment. Enhancement of learning and memory in maze and fear-conditioning paradigms. Modulation of serotonin metabolism in the brain. Immunomodulatory effects including IL-6 and interferon expression. Stabilization of enkephalin levels under stress conditions. Neuroprotective effects against oxidative stress.
Semax is a synthetic heptapeptide analog of ACTH(4-10) — a fragment of adrenocorticotropic hormone that retains the parent hormone’s neurotrophic activity without its hormonal (adrenal-stimulating) effects. The full sequence is Met-Glu-His-Phe-Pro-Gly-Pro, where the Pro-Gly-Pro tail serves the same stabilizing function as in Selank.
In Russia, Semax is approved for clinical use in stroke recovery, cognitive disorders, and optic nerve conditions. It has been used in Russian clinical practice since the 1990s and is available as a prescription nasal spray under the brand name Semax.
The defining feature of Semax is its potent upregulation of brain-derived neurotrophic factor (BDNF). BDNF is one of the most important proteins for brain health — it promotes the survival of existing neurons, encourages the growth of new neurons and synapses (neuroplasticity), and is essential for learning and long-term memory formation. Semax has been shown to increase BDNF expression by up to 300% in certain brain regions in animal studies, making it one of the most potent known peptide modulators of this critical growth factor.
Beyond BDNF, Semax modulates the dopaminergic system, influencing motivation, focus, and reward-related cognition. It also affects serotonin turnover in the brain and has demonstrated neuroprotective effects against ischemic (blood-flow-restricted) brain injury — which underlies its clinical use for stroke recovery in Russia.
Semax benefits documented in research include:
Significant upregulation of BDNF and NGF (nerve growth factor) expression. Enhanced cognitive performance in learning and memory tasks. Neuroprotection against ischemic and oxidative brain damage. Modulation of dopaminergic neurotransmission. Improved attention and information processing speed. Anti-inflammatory effects in neural tissue. Potential applications in optic nerve regeneration research.
The core difference between Selank and Semax lies in their primary neurotransmitter targets and the resulting functional profiles.
Selank operates “bottom-up” through inhibitory modulation. By enhancing GABA activity and stabilizing enkephalin levels, Selank calms overactive stress signaling in the brain. Think of it as reducing the “noise” — lowering anxiety and stress-driven cognitive interference, which allows clearer thinking as a secondary benefit. The cognitive improvement from Selank is primarily a result of removing stress-related barriers to clear cognition, rather than directly stimulating cognitive pathways.
Semax operates “top-down” through neurotrophic stimulation. By dramatically increasing BDNF and modulating dopamine, Semax directly stimulates the brain’s learning, memory, and attention systems. It actively builds new neural connections and strengthens existing ones. The mood benefits of Semax are secondary effects of its dopaminergic and serotonergic modulation, rather than its primary mechanism.
This fundamental difference means the two peptides are highly complementary rather than redundant — Selank addresses the emotional and stress-related side of cognitive performance, while Semax addresses the neurotrophic and attentional side.
| Mechanism | Selank | Semax |
| GABA modulation | Primary mechanism — enhances inhibitory signaling | Minimal direct effect |
| BDNF upregulation | Modest effect | Primary mechanism — up to 300% increase in some brain regions |
| Serotonin modulation | Significant — affects serotonin metabolism | Moderate — affects serotonin turnover |
| Dopamine modulation | Minimal direct effect | Significant — enhances dopaminergic activity |
| Enkephalin stabilization | Significant — stabilizes endogenous opioids | Minimal direct effect |
| Immunomodulation | Strong — retains tuftsin’s immune effects | Moderate |
| Neuroprotection | Via antioxidant and anti-inflammatory pathways | Via BDNF, anti-ischemic, and anti-inflammatory pathways |
| Neuroplasticity | Indirect — via stress reduction | Direct — via BDNF-driven synaptogenesis |
Selank’s research profile makes it the stronger candidate when the research focus involves anxiety-related models, stress resilience, or immune modulation. Studies consistently show Selank produces anxiolytic effects comparable to benzodiazepines without the sedation, motor impairment, or dependence issues that limit those drugs in research settings.
Selank is also of particular interest in social anxiety and generalized anxiety research models, where its GABAergic and enkephalin-modulating effects show promise. Its dual anxiolytic-immunomodulatory profile is unique in the peptide space and makes it relevant to research exploring the intersection of stress, anxiety, and immune function.
Emerging research areas include Selank’s potential role in post-viral cognitive issues where both immune dysregulation and anxiety contribute to symptoms — a growing area of interest since 2020.
Semax is the stronger choice when research focuses on cognitive enhancement, neuroprotection, or neuroregeneration. Its ability to dramatically upregulate BDNF makes it relevant to any research exploring neuroplasticity, learning, memory formation, or recovery from neurological injury.
The peptide’s neuroprotective effects against ischemic injury underlie its approved clinical use for stroke recovery in Russia. Researchers studying models of reduced cerebral blood flow, traumatic brain injury, or neurodegenerative conditions frequently select Semax for its well-documented neurotrophic profile.
Semax is also gaining attention in ADHD-related research due to its dopaminergic modulation, and in research on post-COVID brain fog and cognitive recovery — both emerging keyword searches that reflect growing research interest.
Browse our Semax product page for available formats and purity data
The Semax and Selank stack — combining both peptides in a research protocol — is one of the most widely discussed combinations in the nootropic peptide community. The rationale is straightforward: these peptides target complementary systems, and combining them addresses both the “calm clarity” (Selank) and “active enhancement” (Semax) sides of cognitive performance.
Published research supports the biological plausibility of this combination. Because Selank and Semax operate through different primary mechanisms (GABA/enkephalin vs. BDNF/dopamine), they are unlikely to compete for the same receptors or create redundant effects. Instead, they address cognitive performance from two different angles simultaneously.
Researchers who study this combination typically administer both intranasally, sometimes alternating nostrils for each peptide. The combination is also available as pre-blended nasal sprays from research suppliers, though individual peptides allow more precise control over dosing of each component.
The enhanced versions — N-Acetyl Semax Amidate and N-Acetyl Selank Amidate — are often preferred for stacking due to their improved stability and reported potency. The N-Acetyl modification enhances resistance to enzymatic degradation, while the amidate modification improves blood-brain barrier penetration.
View our Selank product page and Semax product page for research-grade options
Published research protocols for both peptides most commonly use intranasal administration, which allows the peptides to bypass the blood-brain barrier through the nasal mucosa’s direct connection to the olfactory bulb.
Selank dosage in research: Studies typically use doses ranging from 250 mcg to 750 mcg administered intranasally, often divided across multiple administrations per day. Russian clinical protocols commonly reference 200–400 mcg per administration, 2–3 times daily. Study durations typically range from 10 to 14 days in acute protocols, with some studies extending to 30 days.
Semax dosage in research: Published studies use intranasal doses ranging from 200 mcg to 600 mcg per administration, typically 2–3 times daily. The Russian clinical preparation (Semax 0.1%) delivers approximately 50 mcg per drop. Research protocols commonly run 10–14 days, with some neuroprotection studies extending to 30 days or longer.
Both peptides are typically supplied as lyophilized powder that is reconstituted with bacteriostatic water and loaded into nasal spray bottles for intranasal delivery.
See our peptide reconstitution guide for preparation instructions
Peptide reconstitution calculator — calculate your dose-per-spray for nasal delivery
Both Selank and Semax have favorable safety profiles in published research, consistent with their approval for clinical use in Russia.
Selank has not been associated with significant adverse effects in published studies. Unlike benzodiazepines (which target similar anxiety pathways), Selank does not cause sedation, motor impairment, cognitive dulling, or physical dependence. No tolerance development has been documented in the available literature. Mild nasal irritation from the spray delivery vehicle is the most commonly reported side effect in user discussions, though this relates to the delivery method rather than the peptide itself.
Semax is similarly well-tolerated. Some animal studies note mild transient effects related to its dopaminergic activity, but no significant toxicity has been documented. Russian clinical use over decades provides a substantial real-world safety record, though formal pharmacovigilance data from that context may not be fully accessible to Western researchers. As with Selank, nasal irritation from the spray vehicle is the most commonly reported minor complaint.
Neither peptide has shown addictive properties, withdrawal effects, or tolerance development in the published literature — a significant distinction from many conventional anxiolytic and cognitive-enhancing compounds.
Researchers frequently compare Selank to other anxiolytic compounds. The most common comparisons include Selank vs phenibut (a GABAergic compound with significant dependence risk), Selank vs L-theanine (an amino acid with mild calming effects), and Selank vs prescription benzodiazepines. Selank’s advantage in research settings is its anxiolytic efficacy without sedation or dependence — a profile that makes it particularly useful for studying anxiety reduction without confounding motor or cognitive impairment.
Semax is commonly compared to other cognitive-enhancing research compounds. The most frequent comparisons include Semax vs modafinil (a wakefulness-promoting agent that works through different mechanisms), Semax vs noopept (a synthetic nootropic with BDNF-modulating properties), and Semax vs racetams (a class of synthetic nootropics). Semax’s unique advantage is its direct neurotrophic mechanism via BDNF — rather than simply increasing wakefulness or acetylcholine signaling, Semax actively promotes the growth of neural infrastructure, which may produce more durable cognitive effects with continued use.
Based on published research, Selank has a stronger anxiolytic profile than Semax. Selank directly modulates the GABA system — the brain’s primary inhibitory network — and stabilizes enkephalin levels, both of which directly address anxiety-related neurotransmission. Semax may provide indirect mood benefits through BDNF and dopamine modulation, but anxiety reduction is not its primary research focus.
Semax is the stronger choice for research focused on cognition, learning, and memory. Its potent BDNF upregulation directly supports neuroplasticity and synaptic strengthening — the biological foundations of learning and memory formation. Semax also modulates dopamine, which is central to attention and focus. Selank can improve cognitive clarity by reducing anxiety interference, but this is an indirect rather than direct cognitive effect.
Yes — the Selank and Semax stack is widely discussed in nootropic research communities, and the biological rationale is sound. Because the two peptides operate through different primary mechanisms (GABA/enkephalin for Selank, BDNF/dopamine for Semax), they address complementary aspects of cognitive performance without receptor competition. Researchers typically administer both intranasally, sometimes using separate nasal spray devices for each peptide.
N-Acetyl Semax Amidate (NASA) is a modified version of Semax with two structural enhancements: an N-acetyl group at the amino terminus and an amide group at the carboxyl terminus. These modifications increase resistance to enzymatic degradation and may improve blood-brain barrier penetration, potentially enhancing bioavailability and duration of activity compared to standard Semax. The same modifications are available for Selank as N-Acetyl Selank Amidate.
Yes. Both Selank and Semax are legal to purchase and possess in the United States for research purposes. They are not controlled substances and are not scheduled by the DEA. However, they are not FDA-approved for any medical use in the US. They are sold exclusively as research peptides. In Russia, both are approved prescription medications — Selank as an anxiolytic and Semax for cognitive and neurological conditions.
The Selank vs Semax choice ultimately depends on your research priorities. If the primary research focus involves anxiety, stress resilience, or immune modulation, Selank’s GABAergic and enkephalin-modulating profile makes it the stronger candidate. If the focus is cognitive enhancement, neuroprotection, or neuroplasticity, Semax’s BDNF-driven neurotrophic profile is more directly relevant.
For research requiring comprehensive cognitive optimization — addressing both the stress/anxiety side and the direct cognitive enhancement side — the Semax + Selank stack offers a complementary combination supported by sound mechanistic logic.
VMAX Peptides supplies both Selank and Semax at 99%+ purity in research-ready formats, including standard and N-Acetyl Amidate versions. All products include third-party testing verification and Certificates of Analysis.
